MDS 2023 | Genetic mutations and inflammation: understanding the links and improving prognosis in MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, offers insight into the effects of genetics on inflammatory states in patients with myelodysplastic syndromes (MDS). Though genetics are known to be involved in MDS-related inflammation, Prof. Platzbecker emphasizes that its role is still not fully understood. Prof. Platzbecker highlights specific mutations, such as in p53, SF3B1, and IRAK4 pathway mediators, and discusses their links to inflammatory states in MDS. To conclude, Prof. Platzbecker notes that IRAK4 inhibition is under active investigation in clinical trials and may be an avenue to alleviate cytopenia and improve prognosis in patients with MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
